DM002

DM002 is a first-in-class bispecific antibody-drug conjugate (ADC) designed to treat solid tumors by simultaneously targeting HER3 (Receptor tyrosine-protein kinase erbB-3) and MUC1 (Mucin-1). Developed using the RenLite common light chain platform with fully human antibodies, it features a monoclonal antibody structure that enables efficient purification and drug conjugation. The ADC incorporates a novel topoisomerase I inhibitor payload via a cleavable linker with high hydrophilicity and stability. Preclinical studies have demonstrated potent tumor inhibition in models of non-small cell lung cancer, colorectal cancer, and other solid tumors co-expressing HER3 and MUC1. The drug is being developed primarily for advanced malignant solid neoplasms including colorectal cancer, endometrial carcinoma, ovarian cancer, prostatic cancer, breast cancer, pancreatic cancer, and small cell lung cancer[1][3][4][5][7].

Other names

anti-HER3/MUC1 bispecific ADCHER3 x MUC1 BsADCHER-3 x MUC1 BsADCHER 3 x MUC1 BsADC